Valuation: HLS Therapeutics Inc.

Market Cap 93.48M 81.91M 76.04M 69.87M 132M 9.02B 134M 906M 355M 4.41B 351M 343M 15.25B P/E 2026 *
-14.9x
P/E 2027 * -99.6x
Enterprise Value 93.48M 81.91M 76.04M 69.87M 132M 9.02B 134M 906M 355M 4.41B 351M 343M 15.25B EV / Sales 2026 *
1.61x
EV / Sales 2027 * 1.45x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+0.24%
Current month-4.54%
1 month-5.82%
3 months-9.46%
6 months-10.43%
Current year-12.66%
1 week 4.03
Extreme 4.03
4.25
1 month 4
Extreme 4
4.44
Current year 4
Extreme 4
5.25
1 year 4
Extreme 4
5.76
3 years 3
Extreme 3
6.4
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 30/04/2023
Director of Finance/CFO 61 25/01/2024
Chief Tech/Sci/R&D Officer 61 31/05/2014
Director TitleAgeSince
Director/Board Member 58 11/03/2018
Chairman 48 21/06/2023
Director/Board Member 65 31/12/2020
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Option

Chief Financial Officer

50,000 0.1599%
26/06/26 Option

Chief Technology Officer

12,000 0.0384%
26/06/26 Option

Compliance Officer

35,000 0.1119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+0.24%-14.26%-31.54% 93.48M
-1.79%+2.22%+14.74%+96.51% 95.31B
-2.88%-1.96%+40.38%+136.66% 51.65B
+0.17%-1.53%+1.22%+257.41% 23.26B
+0.66%-0.71%-12.67%-17.89% 8.29B
-0.29%-2.00%-29.97%-29.84% 7.98B
+0.06%-4.55%-10.99%-28.42% 6.76B
+0.19%+3.68%+26.54%+28.67% 6.29B
-0.17%+2.58%+0.67%+23.70% 5.48B
-0.20%-1.94%-6.47%-7.22% 3.73B
Average -0.40%+0.12%+0.92%+42.80% 20.88B
Weighted average by Cap. -1.50%+0.58%+15.54%+105.08%

Financials

2026 *2027 *
Net sales 58.03M 50.85M 47.2M 43.37M 81.73M 5.6B 82.94M 562M 220M 2.74B 218M 213M 9.47B 64.31M 56.35M 52.31M 48.07M 90.58M 6.21B 91.92M 623M 244M 3.04B 241M 236M 10.49B
Net income -6.26M -5.49M -5.1M -4.68M -8.82M -604M -8.95M -60.7M -23.76M -296M -23.52M -23.01M -1.02B -1.05M -920K -854K -785K -1.48M -101M -1.5M -10.17M -3.98M -49.58M -3.94M -3.86M -171M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
22/07/26 CA$4.210 +0.24% 8,581
21/07/26 CA$4.200 +2.19% 9,200
20/07/26 CA$4.110 0.00% 8,748
17/07/26 CA$4.110 -1.20% 5,100
16/07/26 CA$4.160 -0.95% 13,214
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.989USD
Average target price
5.179USD
Spread / Average Target
+73.27%

Quarterly revenue - Rate of surprise